

mRNA-1273 COVID-19 vaccine effectiveness against the COVID-19 disease in Qatar

Nature Medicine

27, 1614-1621

DOI: [10.1038/s41591-021-01446-y](https://doi.org/10.1038/s41591-021-01446-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARS- CoV-2 vaccines for holistic management and achieving global control. Turkish Journal of Medical Sciences, 2021, 51, 3157-3161.	0.4	6
8	Does BCG provide long-term protection against SARS-CoV-2 infection? A caseâ€“control study in Quebec, Canada. Vaccine, 2021, 39, 7300-7307.	1.7	13
10	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	6.6	165
13	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554.	1.5	8
18	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ, The, 2021, 374, n1943.	3.0	245
20	Covid-19: How many variants are there, and what do we know about them?: Video 1. BMJ, The, 2021, 374, n1971.	3.0	37
21	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. International Journal of Infectious Diseases, 2021, 112, 52-54.	1.5	59
22	Changes in Mental Health and Preventive Behaviors before and after COVID-19 Vaccination: A Propensity Score Matching (PSM) Study. Vaccines, 2021, 9, 1044.	2.1	26
23	Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. Biomedicines, 2021, 9, 1230.	1.4	8
24	A closer look at U.S COVID-19 vaccination rates and the emergence of new SARS-CoV-2 variants: It's never late to do the right thing. Annals of Medicine and Surgery, 2021, 69, 102709.	0.5	4
27	Beta testing the monkey model. Nature Immunology, 2021, 22, 1201-1203.	7.0	0
28	Shooting at a Moving Targetâ€“Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052.	2.1	22
32	SARS-CoV-2 Variants of Concern. Yonsei Medical Journal, 2021, 62, 961.	0.9	183
33	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clinical Infectious Diseases, 2022, 75, e1188-e1191.	2.9	38
34	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. Npj Vaccines, 2021, 6, 125.	2.9	17
35	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
36	Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Regional Health - Europe, The, 2021, 11, 100249.	3.0	115
37	COVID-19: State of the Vaccination. Drugs and Therapy Perspectives, 2021, 37, 508-518.	0.3	5

#	ARTICLE	IF	CITATIONS
38	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
41	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
45	National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan. <i>Surgery Today</i> , 2022, 52, 763-773.	0.7	7
46	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. <i>Lancet, The</i> , 2021, 398, 1407-1416.	6.3	978
47	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
48	Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <i>In Silico Pharmacology</i> , 2021, 9, 55.	1.8	12
49	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	15.2	450
50	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	3.8	140
51	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. <i>Science</i> , 2022, 375, 331-336.	6.0	202
52	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
53	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
54	Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 132.	1.5	244
55	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , 2021, 21, 2084.	1.2	30
56	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
57	Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100134.	1.5	54
59	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
60	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
61	mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology. <i>Microbial Biotechnology</i> , 2022, 15, 135-148.	2.0	9

#	ARTICLE	IF	CITATIONS
62	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
63	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. <i>Global Epidemiology</i> , 2021, 3, 100068.	0.6	30
66	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
67	Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 398-404.	2.8	90
68	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
69	Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy. <i>Immunity, Inflammation and Disease</i> , 2021, , .	1.3	10
70	Probability of Resurgence and Scale of Transmission of COVID-19 in China Depend on Passive Case Detection Capacity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
71	Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
72	Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries. <i>EClinicalMedicine</i> , 2022, 43, 101253.	3.2	10
74	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. <i>Nature Microbiology</i> , 2022, 7, 277-288.	5.9	37
75	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	2.5	34
76	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
77	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. <i>Med</i> , 2022, 3, 28-41.e8.	2.2	19
78	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
79	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
80	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
82	Risk of SARS-CoV-2 Reinfection and COVID-19 Hospitalisation in Individuals With Natural- and Hybrid Immunity: A Retrospective, Total Population Cohort Study in Sweden. <i>SSRN Electronic Journal</i> , 0, , .	0.4	13
84	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15

#	ARTICLE	IF	CITATIONS
85	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
86	Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1091-1093.	13.9	83
87	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	1.1	1
88	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
89	Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot. <i>Nature Communications</i> , 2022, 13, 612.	5.8	13
90	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
91	County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100191.	1.5	13
93	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. <i>Lancet, The</i> , 2022, 399, 814-823.	6.3	196
94	A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. <i>Vaccine</i> , 2022, 40, 2044-2052.	1.7	11
95	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
97	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
98	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194
99	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	1.2	7
100	Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. <i>Nature</i> , 2022, 602, 148-155.	13.7	93
101	Covid-19 Rates by Time since Vaccination during Delta Variant Predominance. , 2022, 1, .		7
102	Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	20
105	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ, The</i> , 2021, 375, e068848.	3.0	180
106	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54

#	ARTICLE	IF	CITATIONS
107	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
109	mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 607-612.	1.5	7
110	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 277.	2.1	15
111	Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 871-878.	2.8	31
112	Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment. <i>Nanomaterials</i> , 2022, 12, 783.	1.9	10
113	Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. <i>Nature Communications</i> , 2022, 13, 1614.	5.8	117
114	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
117	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311
118	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
119	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e579-e584.	2.9	17
120	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. <i>RNA Biology</i> , 2022, 19, 386-410.	1.5	19
121	Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 146-150.	1.0	0
123	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4
126	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
127	In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. <i>JCI Insight</i> , 2022, 7, .	2.3	9
128	COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1002-1010.	4.6	192
129	Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 781-790.	4.6	191
132	Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0165921.	1.2	2

#	ARTICLE	IF	CITATIONS
134	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
136	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
137	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
138	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 34.	0.3	5
139	Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients. <i>Annals of Military and Health Sciences Research</i> , 2022, 20, .	0.1	0
140	The Analysis of Patterns of Two COVID-19 Outbreak Clusters in China. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4876.	1.2	2
141	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
142	Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers. <i>Vaccine</i> , 2022, 40, 2915-2924.	1.7	5
143	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
144	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
145	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367.	2.9	83
146	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission. <i>Epidemics</i> , 2022, 39, 100567.	1.5	2
147	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
148	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.2	0
149	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
150	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
151	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
152	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93

#	ARTICLE	IF	CITATIONS
153	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168.	2.9	35
154	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
155	SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2022, 22, 439.	1.3	155
156	A Review of Different Vaccines and Strategies to Combat COVID-19. <i>Vaccines</i> , 2022, 10, 737.	2.1	8
157	SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC). <i>Scientific Reports</i> , 2022, 12, 8074.	1.6	5
158	Prolonged Diarrhea Following COVID-19 Vaccination: A Case Report and Literature Review. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 257, 251-259.	0.5	5
159	Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study. <i>BMC Public Health</i> , 2022, 22, .	1.2	4
160	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
161	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
162	Assessing the Effectiveness of COVID-19 Vaccines in Pakistan: A Test-Negative Case-Control Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
163	VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. <i>Bioinformatics</i> , 2022, 38, 3549-3556.	1.8	4
164	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
166	Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium. <i>PLoS ONE</i> , 2022, 17, e0269138.	1.1	3
167	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
168	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
169	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
170	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
171	Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance. <i>Environmental Technology and Innovation</i> , 2022, 27, 102775.	3.0	17

#	ARTICLE	IF	CITATIONS
172	Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1262.	1.5	1
174	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
175	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
176	Comparative COVID-19 Vaccine Effectiveness over Time in Veterans. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	15
177	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. <i>Expert Review of Vaccines</i> , 2022, 21, 1255-1268.	2.0	30
178	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in [®] , in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. <i>EClinicalMedicine</i> , 2022, 50, 101526.	3.2	20
179	Monitoring the COVID-19 immune landscape in Japan. <i>International Journal of Infectious Diseases</i> , 2022, 122, 300-306.	1.5	5
180	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
181	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
182	Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S155-S158.	2.9	3
183	Prevalence and correlates of COVID-19 vaccine hesitancy among the elderly in Qatar: A cross-sectional study. <i>Medicine (United States)</i> , 2022, 101, e29741.	0.4	4
184	COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, .	1.7	6
188	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
189	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. <i>Journal of Global Health</i> , 0, 12, .	1.2	48
190	Impact of the COVID-19 Pandemic on the Physical Activity Profile and Glycemic Control Among Qatari Adults With Type 1 Diabetes: Effect of Vaccination Status. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
192	Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 Genomes. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 963-976.	1.2	7
193	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
194	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. <i>International Journal of Biological Sciences</i> , 2022, 18, 4642-4647.	2.6	4

#	ARTICLE	IF	CITATIONS
196	COVID-19: respiratory disease diagnosis with regularized deep convolutional neural network using human respiratory sounds. <i>European Physical Journal: Special Topics</i> , 2022, 231, 3673-3696.	1.2	4
197	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
198	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. <i>Nature Communications</i> , 2022, 13, .	5.8	33
199	COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e061126.	0.8	7
200	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
202	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
203	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
204	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
205	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
206	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
207	Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. <i>International Journal of Infectious Diseases</i> , 2022, 124, 1-10.	1.5	12
208	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
209	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
210	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq1 1 0.784314 rgBT ₂ /Overlook	0.4	
211	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	14
212	Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study. <i>Vacunas</i> , 2023, 24, 27-36.	1.1	10
213	COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021. <i>PLoS ONE</i> , 2022, 17, e0274008.	1.1	9
214	Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7

#	ARTICLE	IF	CITATIONS
215	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
216	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
217	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
218	Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine. <i>Viruses</i> , 2022, 14, 2023.	1.5	8
220	A comparative overview of SARS-CoV-2 and its variants of concern. <i>Infezioni in Medicina</i> , 2022, 30, .	0.7	6
221	COVID-19: Clinical status of vaccine development to date. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 114-149.	1.1	8
222	Effectiveness of ChAdOx1 nCoV-19 coronavirus vaccine in preventing severe disease and mortality during the second wave of pandemic: A case-case analysis from a tertiary care center in South India. <i>Journal of Acute Disease</i> , 2022, 11, 188.	0.0	1
223	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
224	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
226	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 1541-1573.	1.4	4
227	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
228	Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. <i>BMC Medicine</i> , 2022, 20, .	2.3	51
229	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
230	Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. <i>Military Medical Research</i> , 2022, 9, .	1.9	13
231	Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1471-1485.	2.4	11
233	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
234	SARS-CoV-2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
235	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0

#	ARTICLE	IF	CITATIONS
236	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. <i>New England Journal of Medicine</i> , 2022, 387, 1865-1876.	13.9	37
237	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. <i>Human Vaccines and Immunotherapeutics</i> , 0, , .	1.4	2
238	Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
240	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
242	Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	4
243	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
245	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
247	Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Na ⁺ ve infection. <i>Journal of Infection and Public Health</i> , 2023, 16, 55-63.	1.9	3
248	Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211418.	1.0	4
250	Statistical Analysis of the Impact of COVID-19 on PM2.5 Concentrations in Downtown Quito during the Lockdowns in 2020. <i>Sensors</i> , 2022, 22, 8985.	2.1	0
251	Investigation of SARS-CoV-2 Variants and Their Effect on SARS-CoV-2 Monoclonal Antibodies, Convalescent and Vaccine Plasma by a Novel Web Tool. <i>Diagnostics</i> , 2022, 12, 2869.	1.3	1
252	Efficacy and Safety of COVID-19 Vaccines – An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
254	A Cross Sectional Study on Adherence to COVID Appropriate Behaviour and Contributing Factors among Vaccinated Individuals Attending ENT Out-Patient Department of a Teaching Hospital in India. <i>Bengal Journal of Otolaryngology and Head Neck Surgery</i> , 2022, 30, 70-79.	0.1	0
255	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
256	Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study. <i>Virology Journal</i> , 2022, 19, .	1.4	0
257	Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16958.	1.2	1
258	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
259	Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1

#	ARTICLE	IF	CITATIONS
260	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. <i>Molecules</i> , 2023, 28, 795.	1.7	8
262	Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar. <i>Nature Communications</i> , 2023, 14, .	5.8	4
264	COVID-19 and diabetes mellitus: a review of the incidence, pathophysiology and management of diabetes during the pandemic. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 167-179.	1.2	1
265	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
266	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
267	Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	9
268	Lessons learned from the SARS-CoV-2 pandemic; from nucleic acid nanomedicines, to clinical trials, herd immunity, and the vaccination divide. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 489-506.	2.4	0
269	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 816-827.	4.6	35
270	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. <i>BMC Clinical Pathology</i> , 2023, 16, 2632010X2311612.	0.7	3
271	Effectiveness and adverse effects of astrazeneca and pfizer COVID-19 vaccines among medical students in Oman: A comparative study. <i>Biomedical and Biotechnology Research Journal</i> , 2023, 7, 101.	0.3	1
272	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
274	Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study. <i>Vaccine</i> , 2023, 41, 3556-3563.	1.7	7
275	FcÎ³R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 569-580.	5.9	33
276	Immunology of COVID-19. , 2024, , 52-71.		0
277	Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. <i>Nature Communications</i> , 2023, 14, .	5.8	8
278	Immediate and Contributory Causes of Death in Patients Hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	0
280	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
331	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. <i>Current Microbiology</i> , 2024, 81, .	1.0	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------